# Mobia Medical, Inc.: overview MOBI · Nasdaq · CIK 1489993 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/mobi.md) · [Financials](/companies/mobi/financials.md) · [Filings](/companies/mobi/filings.md) · [Insiders](/companies/mobi/insiders.md) Latest reported revenue: [$13.5m](/filings/0001193125-26-344893.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 11, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-344893). ## Last eight quarters | Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | | Revenue | $m | [5.7](/filings/0001193125-26-257552.md) | [6.7](/filings/0001193125-26-344893.md) | [12.1](/filings/0001193125-26-257552.md) | [13.5](/filings/0001193125-26-344893.md) | | Gross margin | % | [82.1%](/filings/0001193125-26-257552.md) | [82.3%](/filings/0001193125-26-344893.md) | [82.3%](/filings/0001193125-26-257552.md) | [83.2%](/filings/0001193125-26-344893.md) | | Operating margin | % | [(182.0%)](/filings/0001193125-26-257552.md) | [(156.7%)](/filings/0001193125-26-344893.md) | [(140.3%)](/filings/0001193125-26-257552.md) | [(132.7%)](/filings/0001193125-26-344893.md) | | Net margin | % | [(188.2%)](/filings/0001193125-26-344893.md) | [(157.2%)](/filings/0001193125-26-344893.md) | [(146.9%)](/filings/0001193125-26-344893.md) | [(155.8%)](/filings/0001193125-26-344893.md) | | Diluted EPS | $ per share | [(12.97)](/filings/0001193125-26-257552.md) | [(12.44)](/filings/0001193125-26-344893.md) | [(19.30)](/filings/0001193125-26-257552.md) | [(1.10)](/filings/0001193125-26-344893.md) | | Free cash flow | $m | [(9.7)](/filings/0001193125-26-257552.md) | [(11.0) d](/filings/0001193125-26-344893.md) | [(17.8)](/filings/0001193125-26-257552.md) | [(17.2) d](/filings/0001193125-26-344893.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 6-month figure less the 3-month figure. ## Last five fiscal years Not reported. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/mobi/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [SR One Capital Management, LP](/funds/1910264.md) | 2026-06-30 | $26.6m | 1,986,072 | | New +1,986,072 | | [FARALLON CAPITAL MANAGEMENT, L.L.C.](/funds/909661.md) | 2026-06-30 | $15.1m | 1,128,557 | | New +1,128,557 | | [Avidity Partners Management LP](/funds/1791827.md) | 2026-06-30 | $10.7m | 798,282 | | New +798,282 | | [DEERFIELD MANAGEMENT COMPANY, L.P.](/funds/1009258.md) | 2026-06-30 | $9.0m | 670,752 | | New +670,752 | | [Aberdeen Group plc](/funds/1716774.md) | 2026-06-30 | $7.8m | 584,570 | | New +584,570 | | [PERCEPTIVE ADVISORS LLC](/funds/1224962.md) | 2026-06-30 | $7.0m | 523,654 | | New +523,654 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $6.0m | 444,355 | | New +444,355 | | [Rock Springs Capital Management LP](/funds/1595725.md) | 2026-06-30 | $5.6m | 418,200 | | New +418,200 | | [Balyasny Asset Management L.P.](/funds/1218710.md) | 2026-06-30 | $5.2m | 387,500 | | New +387,500 | | [Integral Health Asset Management, LLC](/funds/1773206.md) | 2026-06-30 | $3.4m | 250,000 | | New +250,000 | ## Recent filings [All 82 filings](/companies/mobi/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-16 | 20:31 ET | [8-K/A](/filings/0001193125-26-424158.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-424158 | | 2026-10-16 | 20:30 ET | [8-K/A](/filings/0001193125-26-424150.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-424150 | | 2026-08-11 | 20:47 ET | [10-Q](/filings/0001193125-26-344893.md) | Quarterly report, period 2026-06-30 | 0001193125-26-344893 | | 2026-08-11 | 20:12 ET | [8-K](/filings/0001193125-26-344666.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-344666 | | 2026-08-03 | 21:20 ET | [8-K](/filings/0001193125-26-330853.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-330853 | | 2026-07-15 | 20:11 ET | [8-K](/filings/0001193125-26-304763.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-304763 | | 2026-06-04 | 20:35 ET | [10-Q](/filings/0001193125-26-257552.md) | Quarterly report, period 2026-03-31 | 0001193125-26-257552 | | 2026-05-15 | 20:17 ET | [SCHEDULE 13D](/filings/0001193125-26-226819.md) | Ownership report, active investor | 0001193125-26-226819 | | 2026-05-13 | 21:14 ET | [SCHEDULE 13D](/filings/0001193125-26-221953.md) | Ownership report, active investor | 0001193125-26-221953 | | 2026-05-11 | 21:29 ET | [8-K](/filings/0001628280-26-033685.md) | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001628280-26-033685 | ## Latest annual report No annual report is in coverage. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/7fab3819-9e94-44eb-835c-9e6617685b87) ## About the filer - CIK: 1489993 - Tickers: MOBI - Exchange: Nasdaq - SIC code: 3841 Surgical & Medical Instruments & Apparatus - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:51 ET. No prices; not investment advice.